Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...

Solriamfetol is Axsome’s dopamine and norepinephrine reuptake inhibitor (DNRI), TAAR1 agonist, and 5-HT 1A agonist being developed for the treatment of attention deficit hyperactivity disorder ...

In the treatment of mental health disorders like depression and anxiety, selective serotonin reuptake inhibitors (SSRIs ... Zoloft may also affect dopamine reuptake at higher doses, which could ...

New research finds that a certain daily step count is linked to a lowered risk of depression. Here's what that magic number ...

AXS-12 is a highly selective and potent norepinephrine reuptake inhibitor that regulates cortical dopamine activity, Thorpy said. The agent was approved in 1997 in Europe as an antidepressant.

In addition to its pipeline candidates, Axsome also has US rights to Jazz Pharma's dual-acting dopamine and norepinephrine reuptake inhibitor Sunosi (solriamfetol), used to improve wakefulness in ...

AXS-12 is a highly selective norepinephrine reuptake inhibitor and cortical dopamine modulator. It “regulates noradrenergic activity, which helps increase and maintain muscle tone during ...